Search

Equine Botulinum Neurotoxin D Immune FAB2

Equine Botulinum Neurotoxin D Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype D. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients.

Benzonatate

[L11193] Although it not prone to drug misuse or abuse, benzonatate is associated with a risk for severe toxicity and overdose, especially in children.[A189513] … [A5790] Currently, benzonatate is the only non-narcotic antitussive available as a prescription drug.

Debrisoquine

An adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. … They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.

Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine

diphtheriae_ CRM197 protein carrier, resulting in four drug substances contained in each dose of vaccine. … [L43518] Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, marketed as MENVEO, was first approved by the FDA in 2010.[L43518]

PEG-uricase

PEG-uricase, a polyethylene glycol ("PEG") conjugate of recombinant porcine uricase (urate oxidase), which breaks down the uric acid deposits is being studied in Phase III clinical trials for the treatment … of severe, treatment-refractory gout in the United States in 2006.

Chymopapain

[L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. … Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.

Glibornuride

Glibornuride is a sulfonylurea-type anti-diabetic drug.

Nicaraven

Berahyaluronidase alfa

It is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications

Distearyldimonium